These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 21789188

  • 1. Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats.
    Geschka S, Kretschmer A, Sharkovska Y, Evgenov OV, Lawrenz B, Hucke A, Hocher B, Stasch JP.
    PLoS One; 2011; 6(7):e21853. PubMed ID: 21789188
    [Abstract] [Full Text] [Related]

  • 2. Soluble guanylate cyclase stimulator praliciguat attenuates inflammation, fibrosis, and end-organ damage in the Dahl model of cardiorenal failure.
    Shea CM, Price GM, Liu G, Sarno R, Buys ES, Currie MG, Masferrer JL.
    Am J Physiol Renal Physiol; 2020 Jan 01; 318(1):F148-F159. PubMed ID: 31608671
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats.
    Lang M, Kojonazarov B, Tian X, Kalymbetov A, Weissmann N, Grimminger F, Kretschmer A, Stasch JP, Seeger W, Ghofrani HA, Schermuly RT.
    PLoS One; 2012 Jan 01; 7(8):e43433. PubMed ID: 22912874
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pharmacological Characterization of IW-1973, a Novel Soluble Guanylate Cyclase Stimulator with Extensive Tissue Distribution, Antihypertensive, Anti-Inflammatory, and Antifibrotic Effects in Preclinical Models of Disease.
    Tobin JV, Zimmer DP, Shea C, Germano P, Bernier SG, Liu G, Long K, Miyashiro J, Ranganath S, Jacobson S, Tang K, Im GJ, Sheppeck J, Moore JD, Sykes K, Wakefield J, Sarno R, Banijamali AR, Profy AT, Milne GT, Currie MG, Masferrer JL.
    J Pharmacol Exp Ther; 2018 Jun 01; 365(3):664-675. PubMed ID: 29643251
    [Abstract] [Full Text] [Related]

  • 12. Riociguat for the treatment of pulmonary hypertension.
    Hambly N, Granton J.
    Expert Rev Respir Med; 2015 Jun 01; 9(6):679-95. PubMed ID: 26599488
    [Abstract] [Full Text] [Related]

  • 13. Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension.
    Mittendorf J, Weigand S, Alonso-Alija C, Bischoff E, Feurer A, Gerisch M, Kern A, Knorr A, Lang D, Muenter K, Radtke M, Schirok H, Schlemmer KH, Stahl E, Straub A, Wunder F, Stasch JP.
    ChemMedChem; 2009 May 01; 4(5):853-65. PubMed ID: 19263460
    [Abstract] [Full Text] [Related]

  • 14. The sGC stimulator riociguat inhibits platelet function in washed platelets but not in whole blood.
    Reiss C, Mindukshev I, Bischoff V, Subramanian H, Kehrer L, Friebe A, Stasch JP, Gambaryan S, Walter U.
    Br J Pharmacol; 2015 Nov 01; 172(21):5199-210. PubMed ID: 26282717
    [Abstract] [Full Text] [Related]

  • 15. Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition.
    Fraccarollo D, Galuppo P, Motschenbacher S, Ruetten H, Schäfer A, Bauersachs J.
    Basic Res Cardiol; 2014 Jul 01; 109(4):421. PubMed ID: 24907870
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The chemistry and biology of soluble guanylate cyclase stimulators and activators.
    Follmann M, Griebenow N, Hahn MG, Hartung I, Mais FJ, Mittendorf J, Schäfer M, Schirok H, Stasch JP, Stoll F, Straub A.
    Angew Chem Int Ed Engl; 2013 Sep 02; 52(36):9442-62. PubMed ID: 23963798
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Riociguat reduces infarct size and post-infarct heart failure in mouse hearts: insights from MRI/PET imaging.
    Methner C, Buonincontri G, Hu CH, Vujic A, Kretschmer A, Sawiak S, Carpenter A, Stasch JP, Krieg T.
    PLoS One; 2013 Sep 02; 8(12):e83910. PubMed ID: 24391843
    [Abstract] [Full Text] [Related]

  • 20. Expression and activity of soluble guanylate cyclase in injury and repair of anti-thy1 glomerulonephritis.
    Peters H, Wang Y, Loof T, Martini S, Kron S, Krämer S, Neumayer HH.
    Kidney Int; 2004 Dec 02; 66(6):2224-36. PubMed ID: 15569311
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.